43
Management of Management of DCIS DCIS Fei-Fei Liu Fei-Fei Liu Radiation Oncologist/Senior Radiation Oncologist/Senior Scientist Scientist

Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Embed Size (px)

Citation preview

Page 1: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Management of Management of DCISDCIS

Fei-Fei LiuFei-Fei LiuRadiation Oncologist/Senior ScientistRadiation Oncologist/Senior Scientist

Page 2: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Learning Objectives

1. Describe DCIS.2. Acquire familiarity of local

management for DCIS.3. Understand the role of systemic

treatment for DCIS.4. Appreciate some of the emerging

issues.5. Like radiation oncologists.

Page 3: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

DCIS

Definition

Proliferation of malignant ductal epithelial cells which have not breached the BM.

Page 4: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist
Page 5: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

DCIS

• Rising incidence due to screening

• 15-20% of all newly-diagnosed breast tumours– 90% of DCIS are

mammographically detected

Page 6: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist
Page 7: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist
Page 8: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

DCIS

Diagnosis

• Mostly made on mammography

• Role of mri – – Might be more sensitive, but lacks

specificity– useful to r/o multiple lesions

Page 9: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist
Page 10: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

DCIS

Classifications

Very complex; no single accepted system.

Page 11: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Tissue processing protocolis complex; hence notgeneralizable.

Page 12: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Learning Objectives

1. Describe DCIS.2. Acquire familiarity of local

management for DCIS.3. Understand the role of systemic

treatment for DCIS.4. Appreciate some of the emerging

issues.5. Like radiation oncologists.

Page 13: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Management of DCIS

Options

• Simple Mastecomy– no RCT of SM vs. lump – large or diffuse lesions– involvement of resection margins– no role for AxLND

• Lumpectomy + RT

Page 14: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Four RCT of Lump + RT for DCIS

Page 15: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

UKCCRC; Lancet 362:95, 2003

Page 16: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Why Does Controversy Persist?

RCTs demonstrate benefit to RT in all subgroups but:

– margin width was not measured– tumour sizes missing

Page 17: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist
Page 18: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Identification of a LOW RISK Group

Van Nuys data

Margin WidthNo RT RT RR> 10 mm .03 .02 1.14

1 to <10 mm .20 .12 1.49< 1 mm .58 .30 2.54

Page 19: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Canadian Clinical Practice Guidelines for DCIS

• BCS should be followed by RT

• Mastectomy – large or diffuse lesions– involvement of resection margins

• No axillary dissection

• Omission of RT: small, low grade, no necrosis, negative margins

Olivotto et al, CMAJ 165:912, 2001

Page 20: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

RT Is No Longer Given As Such

Page 21: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Modern Day Breast RT

• Tangential parallel pair

• Intensity Modulated Radiation Therapy (IMRT)

• Achieve optimal dose homogeneity in target volume (breast)

Page 22: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

CT-Simulation

• Diagnostic CT unit with rapid spiral acquisition

• Full 3D dataset• Virtual simulation

software

Page 23: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

CT Based Simulation & Planning

Page 24: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Standard Breast Tangents

Page 25: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

115%

110%

105%

100%

95%

90%

Goal: Dose UniformityWedges IMRT

Page 26: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Pignol et al, JCO 26:2085, 2008

Improved Acute Skin Reaction with IMRT

Page 27: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Doses of RT

1. 4240 cGy/16#/3.5 wks+ boost (10 Gy/5#s)

2. 5000 cGy/25#/5 wks+ boost (10 Gy/5#s)

Page 28: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Quiz #1

Which famous personality had DCIS?

1. Melissa Etheridge2. Liona Boyd 3. Belinda Stronach4. Michael Jackson

Page 29: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Learning Objectives

1. Describe DCIS.2. Acquire familiarity of local

management for DCIS.3. Understand the role of systemic

treatment for DCIS.4. Appreciate some of the emerging

issues.5. Like radiation oncologists.

Page 30: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Tamoxifen in the Management

of DCIS

Page 31: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

The Role of Tamoxifen in the Management of DCIS: NSABP B-

24

• N = 1804• Local excision + RT

Placebo TamoxifenP

All Breast Cancer 13.4% 8.2% 0.0009

Ipsilateral BCInvasive 4.2% 2.1% 0.03Non-invasive 5.1% 3.9% 0.43

Contralateral BC3.4% 2.0% 0.01

Page 32: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

UKDCIS Trial: Effect of Tamoxifen

Page 33: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Why the Difference?

Trial Design

– 33% of patients in Tamoxifen arm of the UK trial had RT

– All patients in B24 had RT before TAMOXIFEN

– Exclusion of positive margins in the UK trial

Page 34: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Why the Difference?

Patient Population

– 34% of patients in B24 were <50 years vs. 9% in the UK Trial

– Both trials showed greatest benefit of Tamoxifen in women <50 years

Page 35: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

NSABP B-24: Toxicity

Page 36: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

3000 women; opened Jan 03

IBIS TrialTam vs. Anastrozole

4000 ER+ve DCIS post-menowomen

Page 37: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Quiz #

What is the IMRT acronym?

1. Intermittent Moderate RT2. Infinite Modulated RT3. Incredibly Modern RT4. Intensity Modulated RT

Page 38: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Learning Objectives

1. Describe DCIS.2. Acquire familiarity of local

management for DCIS.3. Understand the role of systemic

treatment for DCIS.4. Appreciate some of the emerging

issues.5. Like radiation oncologists.

Page 39: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Kuere et al; JCO 27:279, 2009

Page 40: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist
Page 41: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Take-Home Points

1. DCIS accounts for ~20% of newly-diagnosed BC

2. Surgery (mostly lumpectomy)

3. RT reduces the risk of local recurrence

4. There may a subset of women with DCIS that do not benefit from RT

Page 42: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Conclusions

5. Prospective validation of BCS alone is needed

6. Improvements in techniques of surgical resection, pathologic evaluation of DCIS, and adherence to synoptic reporting of DCIS will help identify potential candidates for BCS alone.

Page 43: Management of DCIS Fei-Fei Liu Radiation Oncologist/Senior Scientist

Any Questions?